VNRX vs. CHRS, BIOA, GNLX, CRBP, FBRX, DERM, FATE, PLX, IPHA, and TNXP
Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Coherus Oncology (CHRS), BioAge Labs (BIOA), Genelux (GNLX), Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Innate Pharma (IPHA), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.
VolitionRx vs. Its Competitors
VolitionRx (NYSE:VNRX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
In the previous week, VolitionRx had 7 more articles in the media than Coherus Oncology. MarketBeat recorded 8 mentions for VolitionRx and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 1.28 beat VolitionRx's score of 0.59 indicating that Coherus Oncology is being referred to more favorably in the news media.
8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 10.4% of VolitionRx shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Coherus Oncology has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.
VolitionRx has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
VolitionRx presently has a consensus price target of $3.50, indicating a potential upside of 682.65%. Coherus Oncology has a consensus price target of $4.51, indicating a potential upside of 163.89%. Given VolitionRx's stronger consensus rating and higher possible upside, equities analysts plainly believe VolitionRx is more favorable than Coherus Oncology.
Coherus Oncology has a net margin of 125.90% compared to VolitionRx's net margin of -2,321.14%.
Summary
Coherus Oncology beats VolitionRx on 9 of the 16 factors compared between the two stocks.
Get VolitionRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VolitionRx Competitors List
Related Companies and Tools
This page (NYSE:VNRX) was last updated on 10/17/2025 by MarketBeat.com Staff
